How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care

Expert Review of Molecular Diagnostics

Volumn 12, Issue 1, 2012, Pages 25-37

  Baudhuin, Linnea M ^a   Donato, Leslie J ^a   Uphoff, Timothy S ^b  

^a MAYO CLINIC   (United States)

^b MARSHFIELD CLINIC   (United States)

Author keywords

array comparative genomic hybridization; cell free nucleic acid; chromosomal microarray; circulating nucleic acid; companion diagnostics; fetal DNA; massively parallel sequencing; microRNA; miRNA; molecular diagnostics; next generation sequencing; personalized medicine

Indexed keywords

CETUXIMAB; IMATINIB; MICRORNA; TRASTUZUMAB; VEMURAFENIB;

CHROMOSOME 21; CLINICAL LABORATORY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA EXTRACTION; DNA MICROARRAY; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; MOLECULAR DIAGNOSIS; PATIENT CARE; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PYROSEQUENCING; REVIEW;

BIOLOGICAL MARKERS; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; LABORATORIES; MICROARRAY ANALYSIS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; PATHOLOGY, MOLECULAR; SEQUENCE ANALYSIS, DNA;

EID: 82955189198     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.85     Document Type: Review

References (105)

1. Delfino KR, Serão NVL, Southey BR, Rodriguez-Zas SL. Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. Cancer Genomics Proteomics 8(4), 173-183 (2011).
2. Ha TY. MicroRNAs in human diseases: From cancer to cardiovascular disease. Immune Netw. 11(3), 135-154 (2011). Extensive review of miRNA function, biogenesis and clinical applications.
3. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291(5507), 1304-1351 (2001). (Pubitemid 32173090)
4. McPherson JD, Marra M, Hillier L et al. A physical map of the human genome. Nature 409(6822), 934-941 (2001). (Pubitemid 32165348)
5. Metzker ML. Sequencing technologies-the next generation. Nat. Rev. Genet. 11(1), 31-46 (2010). Detailed review of many current next-generation sequencing platforms.
6. Cullum R, Alder O, Hoodless PA. The next generation: Using new sequencing technologies to analyse gene regulation. Respirology 16(2), 210-222 (2011).
7. Maher CA, Kumar-Sinha C, Cao X et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 458(7234), 97-101 (2009).
8. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl Acad. Sci. USA 100(15), 8817-8822 (2003). (Pubitemid 36899181)
9. Fedurco M, Romieu A, Williams S, Lawrence I, Turcatti G. BTA, a novel reagent for DNA attachment on glass and efficient generation of solid-phase amplified DNA colonies. Nucleic Acids Res. 34(3), e22 (2006).
10. Braslavsky I, Hebert B, Kartalov E, Quake SR. Sequence information can be obtained from single DNA molecules. Proc. Natl Acad. Sci. USA 100(7), 3960-3964 (2003). (Pubitemid 36418139)
11. Ng SB, Bigham AW, Buckingham KJ et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat. Genet. 42(9), 790-793 (2010).
12. Ng SB, Buckingham KJ, Lee C et al. Exome sequencing identifies the cause of a mendelian disorder. Nat. Genet. 42(1), 30-35 (2010).
13. Lupski JR, Reid JG, Gonzaga-Jauregui C et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N. Engl. J. Med. 362(13), 1181-1191 (2010).
14. Regalado ES, Guo DC, Villamizar C et al. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ. Res. 109(6), 680-686 (2011).
15. Galmiche L, Serre V, Beinat M et al. Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy. Hum. Mut. 32(11), 1225-1231 (2011).
16. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat. Genet. 43(7), 663-667 (2011).
17. Hershberger RE, Siegfried JD. Update 2011: Clinical and genetic issues in familial dilated cardiomyopathy. J. Am. Coll. Card. 57(16), 1641-1649 (2011).
18. Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotech. 26(10), 1135-1145 (2008).
19. Dohm JC, Lottaz C, Borodina T, Himmelbauer H. Substantial biases in ultra-short read data sets from high-throughput DNA sequencing. Nucleic Acids Res. 36(16), e105 (2008).
20. Su Z, Ning B, Fang H et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev. Mol. Diagn. 11(3), 333-343 (2011).
21. Natrajan R, Reis-Filho JS. Next-generation sequencing applied to molecular diagnostics. Expert Rev. Mol. Diagn. 11(4), 425-444 (2011).
22. Pop M, Salzberg SL. Bioinformatics challenges of new sequencing technology. Trends Genet. 24(3), 142-149 (2008).
23. Trapnell C, Salzberg SL. How to map billions of short reads onto genomes. Nat. Biotech. 27(5), 455-457 (2009).
24. Koboldt DC, Ding L, Mardis ER, Wilson RK. Challenges of sequencing human genomes. Briefings Bioinform. 11(5), 484-498 (2010).
25. Schadt EE, Turner S, Kasarskis A. A window into third-generation sequencing. Hum. Mol. Genet. 19(R2), R227-R240 (2010).
26. Raffan E, Semple RK. Next generation sequencing-implications for clinical practice. Br. Med. Bull. 99, 53-71 (2011).
27. Ajay SS, Parker SC, Ozel Abaan H, Fuentes Fajardo KV, Margulies EH. Accurate and comprehensive sequencing of personal genomes. Genom. Res. 21(9), 1498-1505 (2011).
28. -1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467(7319), 1061-1073 (2010).
29. Pennisi E. Genomics. 1000 genomes project gives new map of genetic diversity. Science 330(6004), 574-575 (2010).
30. Kingsmore SF, Saunders CJ. Deep sequencing of patient genomes for disease diagnosis: When will it become routine? Sci. Transl. Med. 3(87), 87ps23 (2011).
31. Kohonen-Corish MR, Al-Aama JY, Auerbach AD et al. How to catch all those mutations-the report of the third human variome project meeting, UNESCO Paris. Hum. Mut. 31(12), 1374-1381 (2010).
32. Richards CS, Bale S, Bellissimo DB et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet. Med. 10(4), 294-300 (2008). (Pubitemid 351544132)
33. Bell CJ, Dinwiddie DL, Miller NA et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci. Transl. Med. 3(65), 65ra64 (2011).
34. Trask BJ. Fluorescence in situ hybridization: Applications in cytogenetics and gene mapping. Trends Genet. 7(5), 149-154 (1991). (Pubitemid 121001914)
35. Shaffer LG, Kennedy GM, Spikes AS, Lupski JR. Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: Implications for testing in the cytogenetics laboratory. Am. J. Hum. Gen. 69(3), 325-331 (1997). (Pubitemid 27154678)
36. ten Bosch JR, Grody WW. Keeping up with the next generation: Massively parallel sequencing in clinical diagnostics. J Mol. Diagn. 10(6), 484-492 (2008).
37. Talkowski ME, Ernst C, Heilbut A et al. Next-generation sequencing strategies enable routine detection of balanced chromosome rearrangements for clinical diagnostics and genetic research. Am. J. Hum. Genet. 88(4), 469-481 (2011).
38. Regier DA, Friedman JM, Marra CA. Value for money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability. Am. J. Hum. Genet. 86(5), 765-772 (2010).
39. Bejjani BA, Shaffer LG. Clinical utility of contemporary molecular cytogenetics. Ann. Rev. Genom. Hum. Genet. 9, 71-86 (2008). Comprehensive review of contemporary molecular cytogenetic techniques in research and diagnostics.
40. Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet. Med. 12(11), 742-745 (2010).
41. Oostlander AE, Meijer GA, Ylstra B. Microarray-based comparative genomic hybridization and its applications in human genetics. Clin. Genet. 66(6), 488-495 (2004). (Pubitemid 39562010)
42. Snijders AM, Nowak N, Segraves R et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat. Genet. 29(3), 263-264 (2001). (Pubitemid 33096449)
43. Miller DT, Adam MP, Aradhya S et al. Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am. J. Hum. Gen. 86(5), 749-764 (2010). Evidence-based summary of clinical chromosomal microarray testing compared with G-banded karyotyping.
44. Friedman JM, Baross A, Delaney AD et al. Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation. Am. J. Hum. Gen. 79(3), 500-513 (2006). (Pubitemid 44384259)
45. Vermeesch JR, Fiegler H, de Leeuw N et al. Guidelines for molecular karyotyping in constitutional genetic diagnosis. Eur. J. Hum. Genet. 15(11), 1105-1114 (2007). (Pubitemid 350011675)
46. Fan YS, Jayakar P, Zhu H et al. Detection of pathogenic gene copy number variations in patients with mental retardation by genomewide oligonucleotide array comparative genomic hybridization. Hum. Mut. 28(11), 1124-1132 (2007). (Pubitemid 350036917)
47. Tester DJ, Benton AJ, Train L, Deal B, Baudhuin LM, Ackerman MJ. Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing. Am. J. Cardiol. 106(8), 1124-1128 (2010).
48. Barc J, Briec F, Schmitt S et al. Screening for copy number variation in genes associated with the long QT syndrome: Clinical relevance. J. Am. Coll. Cardiol. 57(1), 40-47 (2011).
49. Tyson C, Harvard C, Locker R et al. Submicroscopic deletions and duplications in individuals with intellectual disability detected by array-CGH. Am. J. Med. Genet. A 139(3), 173-185 (2005). (Pubitemid 41740587)
50. Beaudet AL. Ethical issues raised by common copy number variants and single nucleotide polymorphisms of certain and uncertain significance in general medical practice. Genome Med. 2(7), 42 (2010).
51. Lo YM, Corbetta N, Chamberlain PF et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350(9076), 485-487 (1997). (Pubitemid 27343304)
52. Beaudet AL. Progress toward noninvasive prenatal diagnosis. Clin. Chem. 57(6), 802-804 (2011). Provides an excellent basic overview of the field of noninvasive prenatal diagnosis.
53. Lo YM, Tein MS, Lau TK et al. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am. J. Hum. Genet. 62(4), 768-775 (1998). (Pubitemid 28194317)
54. Lo YM, Hjelm NM, Fidler C et al. Prenatal diagnosis of fetal RHD status by molecular analysis of maternal plasma. N. Engl. J. Med. 339(24), 1734-1738 (1998). (Pubitemid 28555431)
55. Van der Schoot CE, Soussan AA, Koelewijn J, Bonsel G, Paget-Christiaens LG, de Haas M. Non-invasive antenatal RHD typing. Transfus. Clin. Biol. 13(1-2), 53-57 (2006).
56. Daniels G, Finning K, Martin P, Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: Current practice and future prospects. Prenat. Diagn. 29(2), 101-107 (2009).
57. Daniels G, van der Schoot CE, Gassner C, Olsson ML. Report of the third international workshop on molecular blood group genotyping. Vox Sang. 96(4), 337-343 (2009).
58. Scheffer P, van der Schoot C, Page-Christiaens G, de Haas M. Noninvasive fetal blood group genotyping of rhesus D, C, E and of K in alloimmunised pregnant women: Evaluation of a 7-year clinical experience. BJOG 118(11), 1340-1348 (2011).
59. Scheffer PG, van der Schoot CE, Page-Christiaens GC, Bossers B, van Erp F, de Haas M. Reliability of fetal sex determination using maternal plasma. Obstet. Gynecol. 115(1), 117-126 (2010).
60. Malone FD, Canick JA, Ball RH et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N. Engl. J. Med. 353(19), 2001-2011 (2005). (Pubitemid 41609093)
61. Chiu RW, Akolekar R, Zheng YW et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: Large scale validity study. BMJ 342, c7401 (2011).
62. Papageorgiou EA, Karagrigoriou A, Tsaliki E, Velissariou V, Carter NP, Patsalis PC. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat. Med. 17(4), 510-513 (2011).
63. Tong YK, Ding C, Chiu RW et al. Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: Theoretical and empirical considerations. Clin. Chem. 52(12), 2194-2202 (2006). (Pubitemid 44924992)
64. Li Y, Zimmermann B, Rusterholz C, Kang A, Holzgreve W, Hahn S. Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. Clin. Chem. 50(6), 1002-1011 (2004). (Pubitemid 38725787)
65. Li Y, Di Naro E, Vitucci A, Zimmermann B, Holzgreve W, Hahn S. Detection of paternally inherited fetal point mutations for b-thalassemia using size-fractionated cell-free DNA in maternal plasma. JAMA 293(7), 843-849 (2005). (Pubitemid 40250368)
66. Li Y, Holzgreve W, Page-Christiaens GC, Gille JJ, Hahn S. Improved prenatal detection of a fetal point mutation for achondroplasia by the use of size-fractionated circulatory DNA in maternal plasma-case report. Prenat. Diag. 24(11), 896-898 (2004). (Pubitemid 39576805)
67. Liao GJ, Lun FM, Zheng YW et al. Targeted massively parallel sequencing of maternal plasma DNA permits efficient and unbiased detection of fetal alleles. Clin. Chem. 57(1), 92-101 (2011).
68. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993). (Pubitemid 24014542)
69. Nozawa M, Miura S, Nei M. Origins and evolution of microRNA genes in Drosophila species. Genome Biol. Evol. 2, 180-189 (2010).
70. Ach RA, Wang H, Curry B. Measuring microRNAs: Comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechnol. 8, 69 (2008).
71. Chapin SC, Doyle PS. Ultrasensitive multiplexed microRNA quantification on encoded gel microparticles using rolling circle amplification. Analyt. Chem. 83(18), 7179-7185 (2011).
72. Jiang Q, Wang Y, Hao Y et al. miR2 disease: A manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 37(Suppl. 1), D98-D104 (2009).
73. Prosser HM, Koike-Yusa H, Cooper JD, Law FC, Bradley A. A resource of vectors and ES cells for targeted deletion of microRNAs in mice. Nat. Biotechnol. 29(9), 840-845 (2011).
74. Ramsingh G, Koboldt DC, Trissal M et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood 116(24), 5316-5326 (2010).
75. Zhang Y, Li M, Wang H et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J. Surg. 33(4), 698-709 (2009).
76. Rosenwald S, Gilad S, Benjamin S et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod. Pathol. 23(6), 814-823 (2010).
77. Pillai R, Deeter R, Rigl CT et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J. Mol. Diagn. 13(1), 48-56 (2011).
78. Megiorni F, Pizzuti A, Frati L. Clinical significance of microRNA expression profiles and polymorphisms in lung cancer development and management. Pathol. Res. Int. 2011, 780652 (2011).
79. Sozzi G, Pastorino U, Croce CM. MicroRNAs and lung cancer: From markers to targets. Cell Cycle 10(13), 2045-1046 (2011).
80. Bianchi F, Nicassio F, Marzi M et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol. Med. 3(8), 495-503 (2011).
81. Small EM, Frost RJA, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation 121(8), 1022-1032 (2010). Excellent review focusing on the role of miRNAs in cardiovascular biology and as biomarkers of disease.
82. Maes OC, Chertkow HM, Wang E, Schipper HM. MicroRNA: Implications for Alzheimer disease and other human CNS disorders. Curr. Genomics 10(3), 154-168 (2009).
83. Alisi A, Da Sacco L, Bruscalupi G et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab. Invest. 91(2), 283-293 (2011).
84. Wang DZ. MicroRNAs in cardiac development and remodeling. Pediatr. Cardiol. 31(3), 357-362 (2010).
85. Wang N, Zhou Z, Liao X, Zhang T. Role of microRNAs in cardiac hypertrophy and heart failure. IUBMB Life 61(6), 566-571 (2009).
86. Ono K, Kuwabara Y, Han J. MicroRNAs and cardiovascular diseases. FEBS J. 278(10), 1619-1633 (2011).
87. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: Preanalytical and analytical challenges. Clin. Chem. 57(6), 833-840 (2011).
88. Dimou A, Harrington K, Syrigos KN. From the bench to bedside: Biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. Pathol. Res. Int. 2011, 312346 (2011).
89. La Thangue NB, Kerr DJ. Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat. Rev. 8(10), 587-596 (2011).
90. Ross JS. Cancer biomarkers, companion diagnostics and personalized oncology. Biomark. Med. 5(3), 277-279 (2011).
91. Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 363(4), 301-304 (2010). Discusses the emergence of personalized medicine and related issues.
92. Bosworth HB, Granger BB, Mendys P et al. Medication adherence: A call for action. Am. Heart J. 162(3), 412-424 (2011).
93. Tucker G. Pharmacogenetics-expectations and reality. BMJ 329(7456), 4-6 (2004).
94. Evans JP, Meslin EM, Marteau TM, Caulfield T. Genomics: Deflating the genomic bubble. Science 331(6019), 861-862 (2011).
95. Jensen K, Murray F. Intellectual property. Enhanced: Intellectual property landscape of the human genome. Science 310(5746), 239-240 (2005). (Pubitemid 41457177)
96. Baudhuin LM. Determining the optimal approach for government-regulated genetic testing. Clin. Chem. 57(1), 7-8 (2011).
97. Gibbs JN. Regulating molecular diagnostic assays: Developing a new regulatory structure for a new technology. Expert Rev. Mol. Diagn. 11(4), 367-381 (2011). Details the current regulatory system and how it relates to government regulation of molecular diagnostics.
98. Beaudet AL. Which way for genetic-test regulation? Leave test interpretation to specialists. Nature 466(7308), 816-817 (2010).
99. Javitt G. Which way for genetic-test regulation? Assign regulation appropriate to the level of risk. Nature 466(7308), 817-818 (2010).
100. Chiang DY, Getz G, Jaffe DB et al. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat. Method. 6(1), 99-103 (2009).
101. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11(10), 685-696 (2011). Provides a comprehensive review of novel applications in the field of next-generation sequencing, especially as it relates to cancer diagnostics.
102. Ku CS, Naidoo N, Wu M, Soong R. Studying the epigenome using next generation sequencing. J. Med. Gen. 48(11), 721-730 (2011).
103. Campbell PJ, Stephens PJ, Pleasance ED et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 40(6), 722-729 (2008). (Pubitemid 351748860)
104. Hoggatt J. Personalized medicine-trends in molecular diagnostics: Exponential growth expected in the next ten years. Mol. Diagn. Ther. 15(1), 53-55 (2011).
105. Li C. Personalized medicine-the promised land: Are we there yet? Clin. Genet. 79(5), 403-412 (2011).